News

Lutris Pharma has concluded subject enrolment in its Phase II clinical trial of LUT014, a new B-Raf inhibitor designed for topical application to treat acneiform rash due to epidermal growth ...
Chemo rash is one of the most common side effects of cancer treatment. These rashes usually aren’t serious, but they can cause pain, itching, and other uncomfortable symptoms. Chemotherapy, also ...
Topical BRAF inhibitor LUT014 gel significantly reduces acneiform rash from anti-EGFR therapies in patients with colorectal cancer. News & Perspective Tools & Reference CME/CE More ...
Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose-limiting toxicity, today announced that it has secured a $30 million ...
In this study, Patel and her team found that treatment interruptions of anti-EGFR therapy due to acneiform rash occurred in 11 patients in the placebo group, four in the high-dose LUT014 group (P ...
LUT014, a topical BRAF-inhibiting gel, may mitigate acneiform rash in patients receiving EGFR-targeted therapy for colorectal cancer, according to phase II clinical trial results presented by ...
They have continued to see a lot of rashes, including poison ivy, viral rashes, sun-related rashes including phytophotodermatitis and polymorphous light eruption, hand-foot-mouth disease and impetigo.
We tend to think of COVID-19 as a respiratory illness. But, like many viruses, COVID can also affect your skin and cause itchy rashes, dermatologists say.
Hives, also called urticaria, can be related to allergies.But they also appear after a viral infection, including COVID-19. The condition can present as raised, itchy red, pink or flesh-colored bumps.